CY1115640T1 - Διαγνωση και αγωγη εναντι της σχιζοφρενειας - Google Patents

Διαγνωση και αγωγη εναντι της σχιζοφρενειας

Info

Publication number
CY1115640T1
CY1115640T1 CY20141100824T CY141100824T CY1115640T1 CY 1115640 T1 CY1115640 T1 CY 1115640T1 CY 20141100824 T CY20141100824 T CY 20141100824T CY 141100824 T CY141100824 T CY 141100824T CY 1115640 T1 CY1115640 T1 CY 1115640T1
Authority
CY
Cyprus
Prior art keywords
schizophrenia
carbonyl
treatment
present
diagnosing
Prior art date
Application number
CY20141100824T
Other languages
English (en)
Inventor
Masanari Itokawa
Toshio Miyata
Makoto Arai
Original Assignee
Renascience Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renascience Co., Ltd filed Critical Renascience Co., Ltd
Publication of CY1115640T1 publication Critical patent/CY1115640T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Abstract

Η παρούσα εφεύρεση παρέχει μία μέθοδο διάγνωσης της σχιζοφρένειας, και ένα αντιδραστήριο ή συσκευή διάγνωσης της σχιζοφρένειας προς χρήση στη μέθοδο. Η παρούσα εφεύρεση περαιτέρω παρέχει έναν παράγοντα θεραπείας ή βελτίωσης όσον αφορά τη σχιζοφρένεια, ο οποίος είναι αποτελεσματικός ως προς τη βελτίωση ή την αγωγή έναντι της σχιζοφρένειας. Ο παράγοντας θεραπείας ή βελτίωσης όσον αφορά τη σχιζοφρένεια περιέχει έναν εκκαθαριστή καρβονυλίων ή έναν αναστολέα του σχηματισμού πρωτεϊνών που έχουν τροποποιηθεί με καρβονύλιο. Η μέθοδος διάγνωσης της σχιζοφρένειας σύμφωνα με την παρούσα εφεύρεση περιλαμβάνει τη μέτρηση τουλάχιστον μίας παραμέτρου σε ένα άτομο, με την παράμετρο να επιλέγεται από την ομάδα που συνίσταται: (1) σε γενετική ανωμαλία του γονιδίου γλυοξαλάσης Ι· (2) στο επίπεδο έκφρασης ή στη δραστικότητα γλυοξαλάσης I σε ένα βιολογικό δείγμα· (3) στο ποσό μίας καρβονυλικής ένωσης ή μίας πρωτεΐνης που έχει τροποποιηθεί με καρβονύλιο και έγκειται σε μία πρωτεΐνη η οποία έχει τροποποιηθεί με την καρβονυλική ένωση · και (4) το ποσό πυριδοξάλης σε ένα βιολογικό δείγμα.
CY20141100824T 2007-08-20 2014-10-10 Διαγνωση και αγωγη εναντι της σχιζοφρενειας CY1115640T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007214047A JP5288365B2 (ja) 2007-07-17 2007-08-20 統合失調症の検査および治療
EP08792016.1A EP2189537B1 (en) 2007-08-20 2008-07-31 Detection and treatment of schizophrenia

Publications (1)

Publication Number Publication Date
CY1115640T1 true CY1115640T1 (el) 2017-01-04

Family

ID=40378067

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100824T CY1115640T1 (el) 2007-08-20 2014-10-10 Διαγνωση και αγωγη εναντι της σχιζοφρενειας

Country Status (11)

Country Link
US (2) US8809329B2 (el)
EP (2) EP2662453A3 (el)
JP (1) JP5288365B2 (el)
CY (1) CY1115640T1 (el)
DK (1) DK2189537T3 (el)
ES (1) ES2515168T3 (el)
HR (1) HRP20140993T1 (el)
PL (1) PL2189537T3 (el)
PT (1) PT2189537E (el)
SI (1) SI2189537T1 (el)
WO (1) WO2009025159A1 (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8551426B2 (en) 2009-06-12 2013-10-08 Bioneer Corporation Compound for inhibiting activity of ribonuclease, and container for storing nucleic acid containing the same
JP5840124B2 (ja) * 2010-05-14 2016-01-06 公益財団法人東京都医学総合研究所 統合失調症の検出方法
CN102993191B (zh) * 2012-12-18 2015-05-27 苏州大学 一种含有吖内酯与吡唑啉酮的杂环手性化合物及其衍生物、合成方法及用途
CN107148272A (zh) 2014-08-29 2017-09-08 吡哆胺研究有限公司 通过组合吡哆胺化合物和硫胺化合物形成的药物组合物
KR101796390B1 (ko) * 2015-07-24 2017-11-09 동국대학교 산학협력단 Blt 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 조성물
JP6105111B1 (ja) 2016-03-02 2017-03-29 国立大学法人東北大学 自閉スペクトラム症改善用組成物
WO2019008981A1 (ja) * 2017-07-07 2019-01-10 パナソニックＩｐマネジメント株式会社 情報提供方法、情報処理システム、情報端末、及び情報処理方法
JP6924964B2 (ja) * 2017-07-07 2021-08-25 パナソニックＩｐマネジメント株式会社 情報提供方法、情報処理システム、情報端末、及び情報処理方法
WO2019008996A1 (ja) * 2017-07-07 2019-01-10 パナソニックＩｐマネジメント株式会社 情報提供方法、情報処理システム、情報端末、及び情報処理方法
US11932880B2 (en) 2018-02-27 2024-03-19 Kikkoman Corporation Enzyme and method for assaying pentosidine using same
US20220396822A1 (en) * 2019-08-27 2022-12-15 Kikkoman Corporation Method for Measuring Pentosidine and Measurement Kit

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52102431A (en) 1976-02-25 1977-08-27 Kyowa Hakko Kogyo Co Ltd Remedies for mental disorder
JP3507884B2 (ja) 2000-03-07 2004-03-15 新潟大学長 遺伝子発現を指標とする統合失調症の客観的診断法
AU2002249173A1 (en) 2001-01-31 2002-08-12 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Phosphorylated glyoxalase i and its use
JP2003038198A (ja) 2001-07-27 2003-02-12 Univ Niigata 精神分裂病により発現量が変化する遺伝子を規定する核酸を解析する方法
NL1019368C2 (nl) * 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
JP2003212795A (ja) 2002-01-15 2003-07-30 Japan Science & Technology Corp 精神分裂病の診断薬
AU2003244205A1 (en) 2002-07-04 2004-01-23 Mitsubishi Pharma Corporation Method of examining and diagnosing integration dysfunction syndrome
JP2004251865A (ja) 2003-02-19 2004-09-09 Takashi Muramatsu 統合失調症およびアルツハイマー病の検査薬
JP4143498B2 (ja) 2003-07-31 2008-09-03 独立行政法人科学技術振興機構 統合失調症の判定方法
JPWO2005030737A1 (ja) 2003-09-30 2006-12-07 三共株式会社 テトラゾール環又はチアゾリジンジオン環を有するフェニレン誘導体
US20050249823A1 (en) 2003-11-04 2005-11-10 Murphy Tanya K Methods for the prevention or amelioration of neuropsychiatric and related diseases
US7645882B2 (en) 2003-12-05 2010-01-12 Toshio Miyata Inhibitor of protein modification products formation
JP2005278490A (ja) 2004-03-29 2005-10-13 Japan Science & Technology Agency 統合失調症に関与する生物学的マーカーの判定方法およびその利用
JP5079503B2 (ja) 2005-06-07 2012-11-21 株式会社インバイオテックス ラジカルスカベンジャー及び活性酸素消去剤
TW200720261A (en) 2005-08-31 2007-06-01 Sankyo Co Phenylene derivatives

Also Published As

Publication number Publication date
EP2662453A2 (en) 2013-11-13
EP2662453A3 (en) 2014-02-26
SI2189537T1 (sl) 2014-11-28
DK2189537T3 (da) 2014-10-27
HRP20140993T1 (hr) 2014-12-19
US20140335517A1 (en) 2014-11-13
US8809329B2 (en) 2014-08-19
EP2189537A1 (en) 2010-05-26
PL2189537T3 (pl) 2015-01-30
PT2189537E (pt) 2014-10-30
US20120065198A2 (en) 2012-03-15
JP5288365B2 (ja) 2013-09-11
WO2009025159A1 (ja) 2009-02-26
EP2189537B1 (en) 2014-10-08
US20110028470A1 (en) 2011-02-03
ES2515168T3 (es) 2014-10-29
EP2189537A4 (en) 2010-08-11
JP2009039088A (ja) 2009-02-26

Similar Documents

Publication Publication Date Title
CY1115640T1 (el) Διαγνωση και αγωγη εναντι της σχιζοφρενειας
CY1111612T1 (el) Μεθοδος για προβλεψη της αποκρισης σε μια θεραπευτικη αγωγη με εναν αναστολεαδιmερισmου του her
BRPI0602594A (pt) dispositivo e método para determinação rápida da eficácia de processos de esterilização ou desinfecção
CY1122871T1 (el) Μεθοδος ποσοτικου προσδιορισμου για την εκφραση της pd-l1
CY1116089T1 (el) Cd73 ως ενας βιοδεικτης για την παρακολουθηση της εξελιξης νοσων και εκτιμηση της αποτελεσματικοτητας θεραπειων
ECSP088228A (es) Secuencias de nucleótidos que codifican proteínas insecticidas
CY1115439T1 (el) Μεθοδοι και νουκλεϊκα οξεα για αναλυσεις διαταραχων του κυτταρικου πολλαπλασιασμου
EA201992026A1 (ru) Применение биомаркеров при идентификации пациентов, имеющих рак, которые будут характеризоваться наличием восприимчивости к лечению ингибитором prmt5
DK2848938T3 (da) Evaluering af effektiviteten af en behandling hos et individ baseret på st2- niveauer
EA201100965A1 (ru) Биомаркеры для ингибиторов с антиангиогенной активностью
BR112013009713A2 (pt) método para identificação de alta produtividade antagonistas microbianos contra patógenos
ATE454465T1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
DE60239940D1 (de) Verfahren, vorrichtungen und computerprogramme zum verifizieren der integrität einer sonde
CY1110076T1 (el) Μεθοδος για τον καθορισμο της δεκτικοτητας σε αναστολεις chk1
DK2038430T3 (da) Toll-Like-Receptor-4-dysfunktion og de biologiske anvendelser deraf
Cechinel et al. Treadmill exercise induces age and protocol-dependent epigenetic changes in prefrontal cortex of Wistar rats
ATE426168T1 (de) Verwendung von asc als marker fur kolorektalkarzinome
ATE475098T1 (de) Verfahren zur messung von plasmaspiegeln von pentraxin ptx3
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
ATE513929T1 (de) Gene mit einfluss auf die menschliche gedächtnisleistung
ATE550668T1 (de) Verfahren zur identifizierung von patienten mit erhöhtem risiko für ein unerwünschtes herz- kreislauf-ereignis
WO2006065940A3 (en) Identification and use of prognostic and predictive markers in cancer treatment
MX2010002993A (es) Uso de clec1b para la determinacion de riesgo cardiovascular y trombotico.
DE602004017317D1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
ATE472611T1 (de) Verfahren zur diagnose von sepsis durch analyse von cytokine mrna expression